Bayer AG’s Monsanto unit announced a sweeping class settlement agreement designed to resolve both current and future claims alleging that its flagship herbicide Roundup causes cancer — a deal that, if approved, would mark the largest toxic tort settlement in U.S. history and potentially close one of the most expensive chapters in modern corporate litigation.
The settlement, disclosed on February 17, 2025, establishes a $10.9 billion fund to compensate claimants who allege they developed non-Hodgkin lymphoma (NHL) or other cancers after exposure to Roundup’s active ingredient, glyphosate. The agreement covers an estimated 100,000 or more current claims and creates a framework for resolving future claims over a period of years, according to a press release published by BusinessWire.
A Decade of Litigation Comes to a Crossroads
The Roundup litigation has been one of the most consequential mass tort proceedings of the 21st century. It began gaining national attention in 2018, when a California jury awarded school groundskeeper Dewayne “Lee” Johnson $289 million — later reduced to $78.5 million — after finding that Monsanto’s Roundup contributed to his terminal non-Hodgkin lymphoma and that the company had failed to warn consumers of the risk. That verdict, delivered in San Francisco Superior Court, opened the floodgates for tens of thousands of similar lawsuits filed across the country.
Bayer, which acquired Monsanto in 2018 for $63 billion in a deal that was supposed to cement its position as the world’s largest agricultural sciences company, instead inherited a legal quagmire that has consumed billions in legal fees, settlement payments, and reputational damage. The German pharmaceutical and chemical giant initially set aside $10.9 billion in 2020 to resolve approximately 125,000 filed and unfiled claims, but subsequent legal setbacks and new filings complicated those early resolution efforts.
The Structure of the New Class Settlement
The newly announced class settlement agreement is designed to address the shortcomings of Bayer’s previous attempts to resolve the litigation. According to the BusinessWire announcement, the deal establishes a two-tier system: one for current claimants who have already filed suit or retained counsel, and another for future claimants who may develop cancer and allege a connection to Roundup exposure in the years ahead.
Current claimants would receive compensation through a points-based system that takes into account the severity of their diagnosis, the extent of their Roundup exposure, and other factors such as age and medical history. The settlement tiers range from modest payments for lower-tier claims to significantly larger awards for claimants with the most serious diagnoses and strongest exposure histories. Monsanto stated that the agreement was reached after extensive negotiations with plaintiffs’ counsel and is subject to court approval.
Why Previous Settlement Efforts Fell Short
Bayer’s road to this settlement has been anything but smooth. In 2021, the company attempted to create a class action settlement that would have established a scientific panel to determine whether glyphosate causes cancer. That proposal was rejected by U.S. District Judge Vince Chhabria in the Northern District of California, who found that the plan was not fair to future claimants because it would have effectively stripped them of the ability to present their own scientific evidence at trial.
The company then pursued a different strategy, seeking to use state-level legislative and regulatory channels to argue that federal EPA labeling requirements preempted state-law failure-to-warn claims. That argument met mixed results in the courts. In 2023, the U.S. Supreme Court declined to hear Bayer’s appeal in the Hardeman v. Monsanto case, leaving intact a $25 million jury verdict and refusing to rule on the preemption question. The high court’s decision was widely viewed as a significant blow to Bayer’s legal strategy and increased pressure on the company to pursue a comprehensive settlement.
The Science Behind the Controversy
At the heart of the Roundup litigation is a fundamental scientific dispute. In 2015, the International Agency for Research on Cancer (IARC), a unit of the World Health Organization, classified glyphosate as “probably carcinogenic to humans” — a Group 2A designation. That finding became the centerpiece of plaintiffs’ cases across the country.
Monsanto and Bayer have consistently maintained that glyphosate is safe when used as directed and have pointed to regulatory assessments from the U.S. Environmental Protection Agency, the European Food Safety Authority, and other bodies that have concluded the chemical is not likely to be carcinogenic to humans. The EPA reaffirmed its position in an interim registration review decision in 2020, though that decision was later vacated by the Ninth Circuit Court of Appeals, which found that the agency had not adequately addressed certain scientific concerns.
Financial Implications for Bayer
The financial toll of the Roundup litigation on Bayer has been staggering. Beyond the $10.9 billion settlement fund, the company has spent billions more in legal defense costs, individual case settlements, and trial verdicts. Bayer’s stock price has declined significantly since the Monsanto acquisition, with investors repeatedly citing the Roundup liability as a drag on the company’s valuation.
In recent earnings calls, Bayer CEO Bill Anderson has signaled that resolving the Roundup litigation is a top corporate priority. The company has also taken steps to reduce its future exposure by announcing in 2021 that it would remove glyphosate from its residential lawn and garden products in the U.S. market by 2023 — a move aimed at reducing the pool of potential future claimants. Professional and agricultural uses of Roundup, which account for the vast majority of the product’s sales, continue.
What Court Approval Will Require
The class settlement agreement now faces what is likely to be a rigorous judicial review process. Under Federal Rule of Civil Procedure 23, the court must determine that the settlement is fair, reasonable, and adequate, and that the class representatives and their counsel have adequately represented the interests of all class members. Given Judge Chhabria’s previous rejection of Bayer’s 2021 proposal, legal observers expect the court to scrutinize the new deal closely.
Plaintiffs’ attorneys involved in the negotiations have expressed cautious optimism. The involvement of experienced mass tort litigators on both sides — and the extensive negotiation process that preceded the announcement — suggests that the parties have attempted to address the concerns that torpedoed earlier efforts. However, objectors within the plaintiff class could still emerge, and the court will need to evaluate whether the compensation tiers adequately reflect the range of injuries alleged.
Broader Ramifications for Mass Tort Litigation
If approved, the Roundup class settlement would set important precedents for how future mass tort cases involving widely used consumer and agricultural products are resolved. The deal’s framework for handling both current and future claims is particularly noteworthy, as it attempts to balance the interests of people who are already sick with those who may not develop symptoms for years or even decades.
Legal scholars have noted that the case also raises fundamental questions about the role of regulatory science in tort litigation. Monsanto’s argument that EPA approval of glyphosate should shield it from state-law claims — an argument that the Supreme Court has so far declined to endorse — remains a live issue that could resurface in future cases involving other chemicals and products.
What Comes Next for Bayer and Roundup Claimants
For the tens of thousands of individuals who allege that Roundup caused their cancer, the settlement represents a potential path to compensation without the uncertainty and delay of individual trials. For Bayer, it offers the possibility of finally drawing a line under a legal saga that has overshadowed the company’s broader business for nearly a decade.
But significant hurdles remain. The court approval process could take months, and appeals are possible regardless of the outcome. Meanwhile, new Roundup lawsuits continue to be filed, and the scientific debate over glyphosate’s safety shows no signs of abating. What is clear is that the resolution of the Roundup litigation — however it ultimately unfolds — will be studied by lawyers, regulators, and corporate executives for generations to come as a case study in the intersection of science, law, and corporate responsibility.